Straus S E, Croen K D, Sawyer M H, Freifeld A G, Felser J M, Dale J K, Smith H A, Hallahan C, Lehrman S N
Medical Virology Section, National Institute of Allergy and Infectious Disease, Bethesda, MD 20892.
JAMA. 1988 Oct 21;260(15):2227-30.
Forty-seven patients with frequently recurring genital herpes participated in one or more of five sequential trials of oral suppressive therapy with 200 mg of acyclovir three times daily from four to 12 months' duration. The prolonged use of acyclovir was extremely well tolerated, and treatment efficacy was sustained through successive studies. Recurrences in eight patients with repeated treatment "failures" were more effectively suppressed with higher doses of acyclovir. All patients experienced recurrent infections after the treatments were completed; however, the mean time to recurrence following each treatment period became progressively longer, and resumption of suppressive therapy was no longer warranted for ten patients. These data indicate the efficacy and safety of chronic suppressive therapy with acyclovir and the value of interrupting prolonged treatment to assess its further need.
47例复发性生殖器疱疹患者参加了5项连续试验中的一项或多项，这些试验采用口服阿昔洛韦进行抑制治疗，剂量为200mg，每日3次，疗程为4至12个月。长期使用阿昔洛韦耐受性极佳，且在后续研究中治疗效果得以持续。8例反复治疗“失败”的患者，使用更高剂量的阿昔洛韦能更有效地抑制复发。所有患者在治疗结束后均经历了复发性感染；然而，每个治疗周期后的复发平均时间逐渐延长，10例患者不再需要继续进行抑制治疗。这些数据表明阿昔洛韦进行慢性抑制治疗的有效性和安全性，以及中断长期治疗以评估是否进一步需要治疗的价值。
